Jump to navigation Jump to search
Clinical data
Routes of
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • Veterinary use (U.S.)
Pharmacokinetic data
Elimination half-life8 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass329.433 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Trilostane


Most recent articles on Trilostane

Most cited articles on Trilostane

Review articles on Trilostane

Articles on Trilostane in N Eng J Med, Lancet, BMJ


Powerpoint slides on Trilostane

Images of Trilostane

Photos of Trilostane

Podcasts & MP3s on Trilostane

Videos on Trilostane

Evidence Based Medicine

Cochrane Collaboration on Trilostane

Bandolier on Trilostane

TRIP on Trilostane

Clinical Trials

Ongoing Trials on Trilostane at Clinical

Trial results on Trilostane

Clinical Trials on Trilostane at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Trilostane

NICE Guidance on Trilostane


FDA on Trilostane

CDC on Trilostane


Books on Trilostane


Trilostane in the news

Be alerted to news on Trilostane

News trends on Trilostane


Blogs on Trilostane


Definitions of Trilostane

Patient Resources / Community

Patient resources on Trilostane

Discussion groups on Trilostane

Patient Handouts on Trilostane

Directions to Hospitals Treating Trilostane

Risk calculators and risk factors for Trilostane

Healthcare Provider Resources

Symptoms of Trilostane

Causes & Risk Factors for Trilostane

Diagnostic studies for Trilostane

Treatment of Trilostane

Continuing Medical Education (CME)

CME Programs on Trilostane


Trilostane en Espanol

Trilostane en Francais


Trilostane in the Marketplace

Patents on Trilostane

Experimental / Informatics

List of terms related to Trilostane

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome.[1][2]

It was withdrawn from human use in the United States market in April 1994.[3][4] The drug is available in the United Kingdom for use in humans under the brand name Modrenal and is used for treatment of Cushing's disease and for breast cancer treatment.[5][6][7] It was approved in the United States in 2008 for the treatment of Cushing's disease (hyperadrenocorticism) in dogs under the brand name Vetoryl.[8] It was available by prescription in the UK under the Vetoryl brand name for some time before it was approved in the US.[9] The drug is also used to treat the skin disorder Alopecia X in dogs.[3][10][11] It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands.[12][13] In studies of the drug, the most common side effects were vomiting, lack of energy, diarrhea, and weight loss. Trilostane should not be given to a dog that:

  1. has kidney or liver disease;[9][14]
  2. takes certain medications used to treat heart disease;[citation needed]
  3. is pregnant, nursing or intended for breeding [9][14]

The safety and effectiveness of trilostane were shown in several studies. Success was measured by improvements in both blood test results and physical symptoms (increased appetite and activity level, and decreased panting, thirst and urination).[7][15]

Only one other drug, Anipryl (veterinary brand name) selegiline, is FDA-approved to treat Cushing's disease in dogs, but only to treat uncomplicated, pituitary-dependent Cushing's.[16] The only previous treatment for the disease was the use of Mitotane (brand name Lysodren) off-label.[15][17]

It has been used as a progesterone inhibitor.[18]

A number of compounding pharmacies in the US sell the product. Since the US approval of Vetoryl in December 2008,[8] compounding pharmacies are no longer able to use a bulk drug product for compounding purposes, but must prepare the compounded drug from Vetoryl.[19]

It is a 3β-hydroxysteroid dehydrogenase inhibitor.[20]


The compound is prepared from testosterone in a four-step synthesis.


  1. Komanicky P, Spark RF, Melby JC. (1978). "Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis". Journal of Clinical Endocrinology and Metabolism. 47 (5): 1042–1051. doi:10.1210/jcem-47-5-1042. PMID 233687.
  2. Forney, Barbara. "Trilostane for Veterinary Use". Wedgewood Pharmacy. Retrieved 5 April 2011.
  3. 3.0 3.1 Cook, Audrey K. (1 February 2008). "Trilostane: A therapeutic consideration for canine hyperadrenocorticism". DVM 360. Retrieved 5 April 2011.
  4. "Trilostane consumer information". 4 January 2009. Archived from the original on 12 February 2008. Retrieved 3 April 2011.
  5. "Modrenal consumer information". UK. Retrieved 3 April 2011.
  6. "Modrenal". electronic Medicines Compendium UK. Retrieved 3 April 2011.
  7. 7.0 7.1 Braddock, JA, Church, DB, Robertson, ID, Watson, ADJ (October 2003). "Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism" (PDF). Australian Veterinary Journal. pp. 18 of 63. Retrieved 5 April 2011. (PDF)
  8. 8.0 8.1 "Vetoryl approval information". Food and Drug Administration. 5 December 2008. Retrieved 3 April 2011.
  9. 9.0 9.1 9.2 "Vetoryl-Contraindications". NOAH Compendium of Animal Health-National Office of Animal Health UK. Retrieved 3 April 2011.
  10. Hillier, Andrew (2006). "Alopecia: Is an Endocrine Disorder Responsible?" (PDF). Ohio State University Endocrinology Symposium. p. 12 of 67. Retrieved 8 April 2011. (PDF)
  11. Cerundolo, Rosario, Lloyd, David H., Persechino, Angelo, Evans, Helen, Cauvin, Andria (2004). "Treatment of Canine Alopecia X with trilostane" (PDF). European Society of Veterinary Dermatology. Retrieved 16 May 2011. (PDF)
  12. Reusch, Claudia E. (2006). "Trilostane-5 Years of Clinical Experience for the Treatment of Cushing's Disease" (PDF). Ohio State University Endocrinology Symposium. pp. 17–19. Retrieved 5 April 2011. (PDF)
  13. Reusch, Claudia E. (2010). "Trilostane-A Review of a Success Story". World Small Animal Veterinary Association (WSAVA). Retrieved 5 April 2011.
  14. 14.0 14.1 "Dechra US Datasheet-Vetoryl" (PDF). Dechra US. Retrieved 3 April 2011. (PDF)
  15. 15.0 15.1 "Treating Cushing's Disease in Dogs". US Food and Drug Administration. Retrieved 3 April 2011.
  16. "Anipryl consumer information". Vet. Retrieved 3 April 2011.
  17. Reine, NJ. (2007). "Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane". Clinical Tech-Small Animal Practice. Retrieved 5 April 2011.
  18. le Roux PA, Tregoning SK, Zinn PM, van der Spuy ZM (June 2002). "Inhibition of progesterone secretion with trilostane for mid-trimester termination of pregnancy: randomized controlled trials". Human reproduction (Oxford, England). 17 (6): 1483–9. doi:10.1093/humrep/17.6.1483. PMID 12042266.
  19. "VETORYL (trilostane) Capsules Letter - Pharmacy Professionals". Food and Drug Administration. 11 September 2009. Retrieved 3 April 2011.
  20. de Gier J, Wolthers CH, Galac S, Okkens AC, Kooistra HS (April 2011). "Effects of the 3β-hydroxysteroid dehydrogenase inhibitor trilostane on luteal progesterone production in the dog". Theriogenology. 75 (7): 1271–9. doi:10.1016/j.theriogenology.2010.11.041. PMID 21295836.

External links